Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | ADH5 | P11766 | 2/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14116389 | 0.83 | PTK2 (0.49) | PTK2HPGDSADH5SLC22A12ALDH1A1 | |
| SCHEMBL17678907 | 0.80 | PTK2 (0.54) | PTK2HPGDSADH5SLC22A12ALDH1A1 | |
| SCHEMBL17670047 | 0.80 | MAP4K4 (0.51) | PTK2HPGDSADH5ALDH1A1CYP2A6 | |
| SCHEMBL18470671 | 0.74 | XDH (0.50) | PTK2HPGDSADH5SLC22A12XDH | |
| SCHEMBL3584374 | 0.70 | ADH5 (0.59) | HPGDSADH5ALDH1A1TP53CYP2A6 | |
| SCHEMBL17670006 | 0.70 | PTK2 (0.64) | PTK2HPGDSADH5ALDH1A1TP53 | |
| SCHEMBL12457517 | 0.70 | PTK2 (0.64) | PTK2ADH5ALDH1A1HCAR2TP53 | |
| SCHEMBL14092293 | 0.68 | TP53 (0.49) | PTK2HPGDSADH5ALDH1A1HCAR2 | |
| SCHEMBL10200752 | 0.66 | NPC1 (0.32) | HPGDSNPC1RAB9ANPSR1 | |
| SCHEMBL4170881 | 0.66 | HPGDS (0.61) | HPGDSADH5CYP2A6GP6XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011593-B2 | Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors | ALLERGAN, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170226094-A1 | HETEROCYCLE-SUBSTITUTED PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | ALLERGAN, INC. | 2017-08-10 | — | — | US | disclosed |
| US-9650366-B2 | Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors | ALLERGAN, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20170096419-A1 | HETEROCYCLE-SUBSTITUTED PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | ALLERGAN, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9359336-B2 | Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors | ALLERGAN, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160102081-A1 | Heterocycle-substituted Pyridyl Benzothiophenes as Kinase Inhibitors | ALLERGAN, INC. | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102081-A1 | Heterocycle-substituted Pyridyl Benzothiophenes as Kinase Inhibitors | FGFR1, TEK, JAK2 | PTK2 46/4885HPGDS 1688/4885ADH5 3377/4885 |
| US-20170226094-A1 | HETEROCYCLE-SUBSTITUTED PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | FGFR1, TEK, JAK2 | PTK2 46/4885HPGDS 1688/4885ADH5 3377/4885 |
| US-20170096419-A1 | HETEROCYCLE-SUBSTITUTED PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | FGFR1, TEK, JAK2 | PTK2 46/4885HPGDS 1688/4885ADH5 3377/4885 |
| US-10011593-B2 | Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors | FGFR1, TEK, JAK2 | PTK2 46/4885HPGDS 1688/4885ADH5 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.